rilapladib
Phase 2Small molecule
GSKrilapladib is one of 55 small molecule programs targeting Atherosclerosis. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
165 competitors in Atherosclerosis
#DrugCompanyPhaseTrials
1Avandia
Alnylam PharmaceuticalsPhase 3
Depo-Provera
PfizerPhase 3
Estrace
Novo NordiskPhase 3
Colcrys
Alnylam PharmaceuticalsPhase 3
Glucotrol
PfizerPhase 3
Actemra
RochePhase 3
Brilinta
AstraZenecaPhase 3
Ilaris
NovartisPhase 3
Zontivity
Akero TherapeuticsPhase 3
Benicar
CCosette Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Alzheimer's Disease1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rilapladib. EMBL-EBI & Wellcome Sanger Institute.
- [4]